Condition category
Digestive System
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
Manucol LD is an alginate which comes from seaweed. Eating seaweeds is good for you. People in Asia who eat lots of it have less chance of developing certain disease such as bowel cancer and inflammatory bowel disease. Seaweeds are essentially a fibre and this product that is extracted from it (the alginate) is used throughout the food industry in products such as ice creams, sauces and jams, and in a number of medicines such as Gaviscon. The active ingredient in seaweed is not accurately known, however alginates are thought to play a key role in its beneficial effects. Through scientific research, it has been found that these alginates can bind iron and other heavy metals and are not broken down by digestive processes in the gut. It is also known that iron which is unabsorbed can have negative effects on the bowel such as inflammation and changes in the levels of good and bad bacteria in the gut. The researchers carrying out this study are interested in using a form of alginate which is altered for delivery to the human colon. This alginate can bind iron in the colon and so reduce the damaging effects of this highly reactive metal. Here, the effect of various doses of alginates in normal healthy people are studied with a view to taking this forward in patients with inflammatory bowel disease or those at risk of developing bowel cancer. This alginate is found in a range of foods and therefore safe for consumption. This study will test this foodstuff at a higher concentrations to see if it is acceptable and easy to consume on a daily basis.

Who can participate?
The study aims to recruit 16 healthy male or female volunteers over the age of 18 years through advertising at the University of Birmingham and the University Hospitals of Birmingham.

What does the study involve?
Participants are asked to attend 3 visits over a 1 month period. Participants are requested to take the Manucol LD on a daily basis, keep a record of when it is taken and if there are any changes in their bowel habit e.g. frequency. At each of these 3 visits they are asked to provide a stool sample (to assess the levels of good and bad bacteria), have blood tests (as markers of general health) and fill in a quality of life questionnaire.

What are the potential benefits and risks of participating?
There will be no direct benefit to individuals taking part in the study. As the Manucol LD is essentially a foodstuff and found in a number of products on the market no problems are anticipated. However as it is a fibre it may cause some bloating and change to participants’ bowel habit. The disadvantages of taking part are the inconvenience entailed in adhering to study protocol and visit schedule. Another drawback is the minor discomfort associated with the two blood tests at the beginning, middle and end of the study.

Where is the study run from?
University of Birmingham in collaboration with the Wellcome Trust Clinical Research Facility at the Queen Elizabeth Hospital in Birmingham (UK)

When is the study starting and how long is it expected to run for?
October 2014 to August 2015

Who is funding the study?
Medical Research Council (UK)

Who is the main contact?
1. Dr Chris Tselepis (scientific)
2. Dr Tariq Iqbal (public)
3. Mr Pritesh Mistry (public)

Trial website

Contact information



Primary contact

Dr Tariq Iqbal


Contact details

School of Cancer Sciences
Vincent Drive
University of Birmingham
B15 2TT
United Kingdom
07713 575156



Additional contact

Dr Chris Tselepis


Contact details

School of Cancer Sciences
Vincent Drive
University of Birmingham
B15 2TT
United Kingdom
+44 (0) 121 414 2972



Additional contact

Mr Pritesh Mistry


Contact details

School of Cancer Sciences
Vincent Drive
University of Birmingham
B15 2TT
United Kingdom
0121 414 2228

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

A physiological study to assess the acceptability of daily alginate (Manucol LD) consumption in healthy volunteers



Study hypothesis

Consuming a daily alginate (Manucol LD) is acceptable

Ethics approval

NRES Committee West Midlands - Edgbaston, 20/08/2015, ref: 15/WM/0221

Study design

Prospective single-centre non-randomised study

Primary study design


Secondary study design

Non randomised study

Trial setting


Trial type

Quality of life

Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet.


This physiological study aims to look at the acceptability of consuming a daily alginate which is thought to improve colonic health.


1. To evaluate the acceptability of supplementation of Manucol LD in healthy subjects for 28 days.
2. To explore the benefit of Manucol LD on bifidobacteria.

Participants take Manucol LD daily for 28 days. They keep a record of when it is taken and if there are any changes in bowel habit. They attend the study centre 3 times over this period where they provide stool and blood samples and complete a quality of life questionnaire..

Intervention type



Drug names

Primary outcome measure

General acceptability of Manucol LD by the end of the study period

Secondary outcome measures

1. Effect of Manucol LD on quality of life measured over the 1 month period using the SF36 questionnaire
2. Level of bifidobacteria (a bacterium associated with gut health) in stool

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Healthy male or female participants aged 18 years or above
2. In the opinion of the investigator, capable of complying with the study requirements and completing the study
3. Willing and able to give informed consent

Participant type

Healthy volunteer

Age group




Target number of participants


Participant exclusion criteria

Participants who have a current or previous history of gastrointestinal disease will not be eligible to take part in the study.

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

The Wellcome Trust
1st Floor Wellcome Trust Building (Blue Zone) Old Queen Elizabeth Hospital Edgbaston
B15 2TH
United Kingdom

Sponsor information


University of Birmingham

Sponsor details

The University of Birmingham
B15 2TT
United Kingdom
0121 414 7618

Sponsor type




Funder type

Not defined

Funder name

Medical Research Council

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

National government


United Kingdom

Results and Publications

Publication and dissemination plan

Planned publication in a peer reviewed journal

Intention to publish date


Participant level data

Available on request

Basic results (scientific)

Publication list

2019 results in:

Publication citations

Additional files

Editorial Notes

08/04/2019: Publication reference added. 20/04/2018: No publications found, verifying study status with principal investigator. 24/03/2016: Ethics approval information added.